EntroGen
FDA-approved real-time PCR-based companion diagnostic for the detection of KRAS and NRAS mutations in colorectal cancer to support informed treatment decisions
Private Company
Total funding raised: $2.8M
About
FDA-approved real-time PCR-based companion diagnostic for the detection of KRAS and NRAS mutations in colorectal cancer to support informed treatment decisions
Diagnostics
Funding History
3Total raised:$2.8M
Seed$2.5M
Grant$145K
Grant$141K